Framingham Genomic drug discovery news

Boston University founded Framingham Genomic to analyze data from the Framingham Heart Study, an ongoing epidemiological study conducted by the university and the National Heart, Lung and Blood Institute. The study identifies cardiovascular disease risk factors among 5,209 patients living in Framingham, Mass. in 1948, as well as 5,135 patients added in 1971 who represent the offspring of the original cohort and their spouses. The study also compiles data on osteoporosis, arthritis, pulmonary disorders, neurological disorders, deafness and diabetes. ...